Advanced Medical Solutions Group And 2 Other UK Stocks That May Be Trading Below Their Estimated Value

As the UK market grapples with global economic uncertainties, notably influenced by China's sluggish recovery and its impact on commodity-linked stocks, investors are keenly observing the performance of major indices like the FTSE 100 and FTSE 250. In such a volatile environment, identifying undervalued stocks can offer opportunities for those seeking potential value investments; Advanced Medical Solutions Group and two other UK companies may currently be trading below their estimated value.

Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom

Name Current Price Fair Value (Est) Discount (Est) THG (LSE:THG) £0.3914 £0.74 47.1% TBC Bank Group (LSE:TBCG) £51.80 £99.21 47.8% RHI Magnesita (LSE:RHIM) £27.60 £53.38 48.3% Oxford Biomedica (LSE:OXB) £6.41 £12.76 49.8% James Fisher and Sons (LSE:FSJ) £4.89 £9.09 46.2% Ibstock (LSE:IBST) £1.136 £2.27 49.9% GB Group (LSE:GBG) £2.21 £4.26 48.2% Eurocell (LSE:ECEL) £1.135 £2.09 45.6% Anglo Asian Mining (AIM:AAZ) £2.51 £4.99 49.7% Advanced Medical Solutions Group (AIM:AMS) £2.28 £4.39 48.1%

Click here to see the full list of 59 stocks from our Undervalued UK Stocks Based On Cash Flows screener.

Let's uncover some gems from our specialized screener.

Advanced Medical Solutions Group

Overview: Advanced Medical Solutions Group plc develops, manufactures, and distributes products for surgical, woundcare, and wound-closure markets across the UK, Germany, Europe, the US, and internationally with a market cap of £492.03 million.

Operations: The company's revenue is primarily derived from its Surgical segment, which accounts for £183.45 million, and its Woundcare segment, contributing £45.49 million.

Estimated Discount To Fair Value: 48.1%

Advanced Medical Solutions Group is trading at £2.28, significantly below its estimated future cash flow value of £4.39, suggesting undervaluation. The company reported a sales increase to £228.94 million for 2025, with net income rising to £9.95 million from the previous year. Earnings are forecasted to grow at 41.3% annually, outpacing the UK market's growth rate of 12.4%. However, return on equity is expected to remain relatively low at 14.4%.

Our growth report here indicates Advanced Medical Solutions Group may be poised for an improving outlook. Take a closer look at Advanced Medical Solutions Group's balance sheet health here in our report.AIM:AMS Discounted Cash Flow as at Apr 2026

GB Group

Overview: GB Group plc, with a market cap of £513.85 million, offers identity data intelligence products and services across the United Kingdom, the United States, Australia, and other international markets.

Operations: The company generates revenue from three main segments: Identity (£156.59 million), Location (£86.87 million), and Global Fraud Solutions (£37.90 million).

Story Continues

Estimated Discount To Fair Value: 48.2%

GB Group is trading at £2.21, significantly below its estimated future cash flow value of £4.26, highlighting potential undervaluation. The company recently refinanced a GBP 175 million unsecured Revolving Credit Facility maturing in 2030, enhancing financial flexibility. Despite high-quality earnings impacted by large one-off items, GB Group's earnings are projected to grow significantly over the next three years at an annual rate of 37%, outpacing the UK market's growth forecast of 12.2%.

Our comprehensive growth report raises the possibility that GB Group is poised for substantial financial growth. Dive into the specifics of GB Group here with our thorough financial health report.LSE:GBG Discounted Cash Flow as at Apr 2026

Oxford Biomedica

Overview: Oxford Biomedica plc is a contract development and manufacturing organization specializing in delivering therapies globally, with a market cap of approximately £775 million.

Operations: The company's revenue is primarily derived from Manufacturing Services (£81.06 million), Development Services (£60.11 million), Procurement Services (£22.30 million), and Licences, Milestones, and Royalties (£5.27 million).

Estimated Discount To Fair Value: 49.8%

Oxford Biomedica is trading at £6.41, well below its estimated future cash flow value of £12.76, suggesting potential undervaluation. The company has launched a fast-track development and manufacturing offering for viral vectors, enhancing its service efficiency and appeal to biotech clients. Despite reporting a net loss of £30.13 million in 2025, Oxford Biomedica's earnings are projected to grow significantly over the next three years as it becomes profitable, supported by strategic partnerships like the expanded agreement with Bristol Myers Squibb.

Our expertly prepared growth report on Oxford Biomedica implies its future financial outlook may be stronger than recent results. Click here and access our complete balance sheet health report to understand the dynamics of Oxford Biomedica.LSE:OXB Discounted Cash Flow as at Apr 2026

Taking Advantage

Unlock our comprehensive list of 59 Undervalued UK Stocks Based On Cash Flows by clicking here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Looking For Alternative Opportunities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AIM:AMS LSE:GBG and LSE:OXB.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments